Tomopenem. Carbapenem antibiotic

Drugs of the Future

Volumn 32, Issue 1, 2007, Pages 37-44

  Revill, P ^a   Serradell, N ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; BIAPENEM; CARBAPENEM; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN; CS 023; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PANIPENEM; R 115685; R 1558; RO 4098463; TOMOPENEM; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL;

EID: 34247596511     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.01.1070582     Document Type: Article

References (42)

1. Kawamoto, I., Shimoji, Y., Kanno, O. et al. Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. J Antibiot 2003, 56(6): 565-79.
2. Kawamoto, I., Shimoji, Y., Kanno, O. et al. R-115685, a novel parenteral carbapenem: Synthesis and structure-activity relationships. 40th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Toronto) 2000, Abst F-1229.
3. Kasai, T., Fujimoto, K. (Sankyo Co., Ltd.). Process for producing carbapenem-type antibacterial. EP 1338596, JP 2002212183, US 2003225055, US 2006009508, US 7091363, WO 0240482.
4. Kawamoto, I., Fukuhara, H., Shimoji, Y. (Sankyo Co., Ltd.). Crystalline 1-methylcarbapenem derivatives. JP 2001072681, US 2002128254, US 2003158174, US 2003232803, US 6924279, WO 0102401.
5. Kawamoto, I., Shimoji, Y., Fukuhara, H. (Sankyo Co., Ltd.). Antimicrobial agent comprising crystalline carbapenem compound. JP 2002161034.
6. Bad bugs, no drugs. As antibiotic discovery stagnates, a public health crisis brews, July 2004. http://www.idsociety.org.
7. Guignard, B., Entenza, J.M., Moreillon, P. β-Lactams against methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2005, 5(5): 479-89.
8. Hooper, D. New antibiotics against multi-resistant Gram-negative bacteria. 5th Int Symp Antimicrob Agents Resist (ISAAR) (April 27-29, Seoul) 2005, Lecture No. N-2.
9. Hikida, M., Terashima, S., Sato, Y., Okamoto, R., Inoue, M. Comparative antibacterial activity of carbapenems against P. aeruginosa (1). Jpn J Anbitiot 2001, 54: 571-9.
10. Sader, H.S., Cerbara, E.F., Luz, D. et al. Evaluation of the cephalosporins, cefepime, cefpirome and ceftazidime, against clinical isolates of imipenem-resistant Pseudomonas aeruginosa. Braz J Infect Dis 1999, 3: 231-7.
11. Quinn, J.P., Dudek, E.J., DiVincenzo, C.A., Lucks, D.A., Lerner, S.A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis 1986, 154: 289-94.
12. Jones, M.E., Cohen, M.A., Brown, N.P., Dannemann, B., Sahm, D.F. Bactericidal activity of RO4908463 (CS-023) against beta-lactam-susceptible and resistant target species. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst E-227.
13. Masuda, N., Ohya, S., Takenouchi, T. et al. R-115685, a novel parenteral carbapenem: Mode of action and resistance mechanisms. 40th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Toronto) 2000, Abst F-1231.
14. Thomson, K.S., Moland, E.S. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J Antimicrob Chemother 2004, 54(2): 557-62.
15. Moland, E.S., Black, J.A., Lockhart, T.J., Thomson, K.S. CS-023: An investigational carbapenem with enhanced activity against resistant pathogens. 42nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Diego) 2002, Abst F-325.
16. Ohya, S., Abe, T., Ishii, C., Kakuta, M., Masuda, N., Kuwahara, S. R-115685, a novel parenteral carbapenem: In vitro antibacterial activity. 40th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Toronto) 2000, Abst F-1230.
17. Koga, T., Abe, T., Inoue, H. et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob Agents Chemother 2005, 49(8): 3239-50.
18. Fukuoka, T., Puechler, K., Rennecke, J., Kuwahara, S. In vitro activity of CS-023 against European clinical relevant bacterial isolates. 42nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Diego) 2002, Abst F-326.
19. Jones, M.E., Draghi, D.C., Thornsberry, C., Flamm, R.K., Karlowsky, J.A., Sahm, D.F. Activity of RO4908463 (CS-023), an investigational carbapenem, against select Gram-positive and Gram-negative pathogens. 44th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 30-Nov 2, Washington, D.C.) 2004, Abst E-2017.
20. Jones, M.E., Nicolau, D.P., Kuti, J.L., Nightingale, C., Draghi, D.C., Flamm, R.K., Sahm, D.F. Activity and pharmacodynamics of RO490-8463 (CS-023), a carbapenem with activity against MRSA. Clin Microbiol Infect [15th Eur Congr Clin Microbiol Infect Dis (ECCMID) (April 2-5, Copenhagen) 2005] 2005, 11(Suppl. 2): Abst P1573.
21. Jones, M.E., Cohen, M.A., Brown, N.P., Dannemann, B., Sahm, D.F. Baseline profile of RO4908463 (CS-023) against recent isolates of target Gram-positive pathogens exhibiting key resistance phenotypes. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Rrancisco) 2006, Abst E-228.
22. Jones, M.E., Cohen, M.A., Brown, N.P., Dannemann, B., Sahm, D.F. Baseline profile of RO4908463 (CS-023) against recent isolates of target Gram-negative pathogens exhibiting beta-lactam resistance phenotypes. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst C2-1835.
23. Tomozawa, T., Sugihara, C., Oyama, T., Koga, T., Fukuoka, T., Kuwahara, S. Postantibiotic effects (PAEs) of CS-023 (RO4908463) against Staphylococcus aureus and Pseudomonas aeruginosa. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-632.
24. Jones, M.E., Cohen, M.A., Brown, N.P., Dannemann, B., Sahm, D.F. RO4908463 (CS-023) demonstrates a low potential for in vitro selection of resistance in S. aureus (SA) E. coli (EC) and P. aeruginosa (PA). 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst C1-35.
25. Noel, A.R., Bowker, K.E., MacGowan, A.P. The RO4908463 (CS-023) T>MIC antibacterial effect relationship for MRSA established in an in vitro pharmacokinetic model of infection. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-638.
26. Noel, A.R., Bowker, K.E., MacGowan, A.P. The antibacterial effect of RO4908463 (CS-023) on MRSA studied in an in vitro pharmacokinetic model of infection. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-637.
27. Kuti, J.L., Nightingale, C., Nicolau, D.P. Pharmacodynamics of RO4908463 (CS-023), a novel carbapenem, against Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PSA). 44th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 30-Nov 2, Washington, D.C.) 2004, Abst A-141.
28. Sun, H.K., Kuti, J.L., Nightingale, C., Nicolau, D.P. Pharmacodynamics of RO4908463 (CS-023) for the empiric treatment of nosocomial pneumonia. 42nd Annu Meet Infect Dis Soc Am (IDSA) (Sept 30-Oct 3, Boston) 2004, Abst 320.
29. Koga, T., Fukuoka, T., Ishii, C. et al. CS-023 (R-115685), a novel parenteral carbapenem: I. In vitro and in vivo pharmacodynamic (PD) evaluations against Pseudomonas aeruginosa. 41st Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 22-25, Chicago) 2001, Abst F-365.
30. Fukuoka, T., Koga, T., Ishii, C. et al. CS-023 (R-115685), a novel parenteral carbapenem: II. In vitro and in vivo activities against methicillin-resistant Staphylococcus aureus. 41st Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 22-25, Chicago) 2001, Abst F-366.
31. Namba, E., Inoue, H., Koga, T., Fukuoka, T., Simpson, I. High affinity for PBP 2′ enables RO490-8463 (CS-023), a unique guanidine-pyrrolidine carbapenem, to achieve good in vitro activity against MRSA, which is confirmed in murine infection models. Clin Microbiol Infect [15th Eur Congr Clin Microbiol Infect Dis (ECCMID) (April 2-5, Copenhagen) 2005] 2005, 11(Suppl. 2): Abst P1572.
32. Ohya, S., Fukuoka, T., Kawada, H., Kubota, M., Kitayama, A., Abe, T., Kuwahara, S. R-115685, a novel parenteral carbapenem: In vivo antibacterial activity. 40th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Toronto) 2000, Abst F-1232.
33. Fukuoka, T., Koga, T., Ishii, C. et al. Antibacterial activity of CS-023 against MRSA and Pseudomonas aeruginosa. 42nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Diego) 2002, Abst F-324.
34. Shibayama, T., Yamamura, N., Matsushita, Y., Tokui, T., Hirota, T., Ikeda, T. Renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in rabbits in comparison with meropenem. Xenobiotica 2006, 36(12): 1273-87.
35. Yamamura, N. CS-023 (RO4908463) and meropenem exhibit different renal excretion behaviour in rabbits. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-1940.
36. Shibayama, T., Matsushita, Y., Kawai, K., Hirota, T., lkeda, T., Kuwahara, S. Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals. Antimicrob Agents Chemother 2007, 51(1): 257-63.
37. Shibayama, T., Matsushita, Y., Kikuchi, N., Kawai, K., Hirota, T., Kuwahara, S. R-115685, a novel parenteral carbapenem: Pharmacokinetics and metabolism in laboratory animals. 40th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Toronto) 2000, Abst F-1233.
38. Shibayama, T., Matsushita, Y., Kurihara, A., Hirota, T., Ikeda, T. Prediction of pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in humans using animal data. Xenobiotica 2007, 37(1): 91-102.
39. Rennecke, J., Hirota, T., Shibayama, T. et al. Safety, tolerability, and pharmacokinetics (PK) of CS-023, a new parenteral carbapenem, in healthy male volunteers. 42nd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Diego) 2002, Abst F-327.
40. Shibayama, T., Matsushita, Y., Hirota, T., Ikeda, T., Kuwahara, S. Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob Agents Chemother 2006, 50(12): 4186-8.
41. Sesoko, S., Morita, K., Tajima, N., Nakashima, M. Safety, tolerability, and pharmacokinetics of CS-023 (RO4908463), a new parenteral carbapenem in healthy Japanese male volunteers. 46th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst A-1941.
42. Maeda, N., Hosokawa, T., Sharo, S., Manabe, S., Kuwahara, S. R-115685, a novel parenteral carbapenem: Preclinical safety studies. 40th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Toronto) 2000, Abst F-1234.